Transcatheter Treatment of Mitral Regurgitation

Echocardiography, cardiac magnetic resonance (CMR), and cardiac computed tomography (CT) may provide complementary information to guide patient and device selection. Evaluation of mitral valve anatomy, identification of MV lesion, and quantification of defect severity should be integrated by comprehensive preprocedural assessment of chamber size, biventricular systolic and diastolic function, hemodynamic impact, and aortic or peripheral vascular disease.

Durability is a major limitation with bioprosthetic heart valves. For mitral valve prosthesis dysfunction, redo surgical mitral valve replacement (rSMVR) has been the mainstay of treatment; however, transcatheter mitral valve-in-valve replacement (mViV) has emerged as a viable alternative. Data comparing these procedures remains limited; therefore, we sought to compare the real-world in-hospital mortality, likelihood of adverse peri-operative outcomes, and predictors of mortality between rSMVR versus mViV using the National Inpatient Sample.

In patients with severe valvular heart disease, guideline-based surgical valve replacement or transcatheter implantation of a prosthetic heart valve is associated with improved survival and relief of symptoms. Prosthetic heart valves are designed to replicate the function of native valves by maintaining unidirectional blood flow and can be separated into two broad categories, mechanical and bioprosthetic (also called tissue) valves, each with different advantages and disadvantages.

In patients with severe valvular heart disease, guideline-based surgical valve replacement or transcatheter implantation of a prosthetic heart valve is associated with improved survival and relief of symptoms. Prosthetic heart valves are designed to replicate the function of native valves by maintaining unidirectional blood flow and can be separated into two broad categories, mechanical and bioprosthetic (also called tissue) valves, each with different advantages and disadvantages.

In patients with severe valvular heart disease, guideline-based surgical valve replacement or transcatheter implantation of a prosthetic heart valve is associated with improved survival and relief of symptoms. Prosthetic heart valves are designed to replicate the function of native valves by maintaining unidirectional blood flow and can be separated into two broad categories, mechanical and bioprosthetic (also called tissue) valves, each with different advantages and disadvantages.

In patients with severe valvular heart disease, guideline-based surgical valve replacement or transcatheter implantation of a prosthetic heart valve is associated with improved survival and relief of symptoms. Prosthetic heart valves are designed to replicate the function of native valves by maintaining unidirectional blood flow and can be separated into two broad categories, mechanical and bioprosthetic (also called tissue) valves, each with different advantages and disadvantages.

Advance your transseptal skillset for structural heart procedures with the technical and clinical guidance of expert faculty. These courses provide didactic and hands-on training designed for Interventional Cardiologists who perform complex left heart procedures, such as mitral valve repair and LAA occlusion.

Surgical treatment of mitral valve diseases has become minimally invasive. This study analyzed the follow-up results of patients after mitral valve repairs (MVRep) using the da Vinci robot.

This broadcast brings together an international faculty to discuss the timely treatment of Degenerative Mitral Valve Regurgitation (DMR) in patients in Europe. Highlighting the most innovative and advanced treatment strategies this programme will provide focus on breakthrough therapy and the program of HARPOON Mitral Valve Repair System including a Live in a Box case introduced by Prof Nicolas Doll.

Certain patients with HF and secondary mitral regurgitation outside the current indication for transcatheter mitral valve repair benefited from the procedure, according to results of the MitraClip Global EXPAND Study.

The risk of liberating embolic debris is inherent to most, if not all, structural heart interventions. Large-bore device placement within the heart chambers, particularly via a transseptal or transaortic approach, and substantial interaction with cardiac structures may release acute or chronic thrombus, cardiac tissue, and device-related material into the bloodstream. One major consequence, cerebral embolism, is one of the most dreadful periprocedural complications of left-sided structural heart interventions. Ongoing research on cerebral embolic protection devices aims to further improve outcome in patients undergoing transcatheter aortic valve replacement (TAVR)1.

GDMT, defined as triple therapy consisting of beta-blockers, RAS inhibitors and MRAs, was associated with a reduced risk of 2-year mortality after TEER for SMR. Optimisation of medical therapy is crucial to improve clinical outcomes in patients undergoing TEER for SMR.

The presence of chronic obstructive pulmonary disease is not associated with intra-hospital or 1-year outcomes for patients with mitral regurgitation undergoing transcatheter mitral valve repair, data from a single-center study show.

With several years of experience in treating valve defects and problems, the Top mitral valve repair surgeons of India offer a high success rate along with the best service. The mitral valve repair surgery success rate in India is very high, and they have sent numerous successfully recovered happy patients home with total satisfaction. After mitral valve repair in India, 95% of sufferers are free of reoperation at 10 years, and this determines about 90% at 25 years.

The network is an international consortium, sponsored by the National Heart, Lung and Blood Institute, that provides infrastructure for proof-of-concept studies and interventions to improve outcomes for patients with cardiovascular disease. It is supported by the National Institutes of Health and other research organizations in the United States, Canada and Germany.

The association of MVP and SCD is supported by several clinical, electrocardiographic, and imaging findings. However, there is no single risk marker, nor any specific combination of them, that has proved to be a consistent predictor of malignant VAs and SCD in patients with MVP. Therefore, further research is needed to validate the existing risk markers, improve our understanding of the underlying arrhythmogenic mechanisms, and establish optimal evidence-based treatment strategies.

Percutaneous atrioventricular valve repair in adults with CHD is feasible with the MitraClip but requires significant preprocedural planning and a multidisciplinary team that combines CHD and interventional therapeutic expertise.

At 1 year, the PASCAL Ace implant system demonstrated feasibility in this early, compassionate use experience in a small group of symptomatic patients with anatomically complex MR. The unique features of the PASCAL Ace implant may expand the treatable MR population.

Balloon-assisted Perclose suture delivery facilitates successful vascular closure following large-bore access. Use of a balloon in the CFA provides counterpressure to assist delivery of the sliding suture knot and a fluoroscopic marker to confirm that the suture has been delivered to the vessel wall.

In this landmark analysis of the MITRA-FR trial, the cumulative rate of HF hospitalisation between 12 and 24 months among patients treated with TMVR on top of GDMT was approximately half as many as those of patients treated with GDMT alone, a difference which did not reach statistical significance in the setting of a low number of events.

The global Transcatheter Heart Valve Replacement Repair Market is expected to stimulate at a good rate In Upcoming Years. Virtual consultations are amongst the ongoing trends. They mitigate the spreading of contagious ailments, thereby facilitating better efficiency. The gap regarding the demand-supply ratio could also be bridged this way. With this practice being followed, the developing economies would benefit better, as the cost to commute could be curtailed.

The TendyneTM transcatheter mitral valve replacement system (Tendyne-TMVR, Abbott Structural Heart, Santa Clara, California) is a therapy for patients with symptomatic mitral valve (MV) disease high risk for conventional MV surgery or challenging anatomy for transcatheter MV repair. With over 1000 Tendyne-TMVR performed worldwide and beneficial periprocedural, 30-day, and 2-year outcomes, the aim of this article is to present best practice recommendations from expert centers performing Tendyne-TMVR to support optimal outcomes (Figure 1).

A multidisciplinary team of interventional cardiologists and a cardiothoracic surgeon performed Louisville’s first successful transcatheter replacement of a native mitral valve this week. The team with Norton Heart & Vascular Institute Structural Heart Program used a transcatheter aortic valve (commonly referred to as TAVR) to replace the patient’s mitral valve that was unable to be treated with standard techniques.